Company Working With Partners on 'Revolutionary' Lung Cancer Trial
Reprint from Pfizer World
Pfizer, Cancer Research UK, and AstraZeneca announce pioneering clinical trial.
As part of its commitment to working with partners around the world to improve the development of oncology therapies, Pfizer is partnering with Cancer Research UK and AstraZeneca on the National Lung Matrix trial. Announced last week, the trial will give researchers access to drugs developed by Pfizer and AstraZeneca, allowing several to be tested at the same time within one trial. Researchers will use the genetics of each lung tumor to identify small groups of patients who, because of the specific genetic changes causing their cancer, are more likely to benefit from a certain drug.
“As our understanding of cancer biology has evolved, we have learned that targeting the genetic abnormalities within a cancer can lead to meaningful improvements in care for that disease,” said Mace Rothenberg, Senior Vice President, Clinical Development and Medical Affairs, and Chief Medical Officer, Pfizer Oncology. “We believe the innovative design of the National Lung Matrix trial may hold significant potential for patients with advanced lung cancer.”
The National Lung Matrix trial is scheduled to open later this year at centers across the United Kingdom.